With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues to evolve. To date, the MS market has accommodated a role for many options owing to disease heterogeneity, individualized treatment decisions, and the unique clinical profile that defines each DMT. That said, with each new launch—and the recent start of generics competition for Tecfidera—players in this space must assess where their products fit in an increasingly crowded market, especially next-in-class alternatives offering incremental benefits. Meanwhile, competing paradigms of escalation versus early intervention with high-efficacy drugs remain. This national patient-level claims data analysis explores the current DMTs’ positioning, examines line of therapy progression, and assesses persistence and compliance by brand.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
- How have newer entrants such as Mayzent and Vumerity been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of MS patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan, Novartis, Sanofi Genzyme, Teva.
Key drugs covered: Aubagio, Copaxone / glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia.
Key analysis provided:
- Brand/therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients. In addition, the dashboard features multiple data refreshes after report publication.
- Multiple Sclerosis - Current Treatment - Treatment Algorithms - Claims Data Analysis: Multiple Sclerosis - Refreshed Dashboard 2021 (US)
- Treatment Algorithms CDA Multiple Sclerosis 2021 Refreshed Dashboard
Author(s): Jonathan Searles; Arava Suresh, M.Pharm.
Jonathan W. Searles is a senior director on the CNS/Ophthalmology Disorders team at Clarivate. In this role, he oversees the team’s syndicated research stream in neurology, with a core focus on multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, migraine, and ischemic stroke. He earned his bachelor’s degree at Brandeis University, where he graduated summa cum laude.
Suresh Arava, M.Pharm., is a research associate on the CNS/Ophthalmology Disorders team at Clarivate. He earned a master’s degree in pharmaceutical administration and management from Manipal University in India.